Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(3):529–534. doi: 10.1054/bjoc.1999.0958

A unified definition of clinical anthracycline resistance breast cancer

X Pivot 1, L Asmar 2, A U Buzdar 2, V Valero 2, G Hortobagyi 2
PMCID: PMC2363337  PMID: 10682660

Abstract

The purpose of the study was to determine the response rates (RR) and duration to second- and third-line chemotherapy programmes in patients with anthracycline-resistant breast cancer, utilizing various definitions of anthracycline resistance. This was a retrospective analysis performed on 1335 patients with metastatic breast cancer who participated in consecutive clinical trials of first line, anthracycline-containing combination chemotherapy (ACCC) at the University of Texas MD Anderson Cancer Center between July 1973 and April 1980. Anthracycline-resistant groups were identified using definitions of anthracycline resistance found in the literature: progressive disease as best response to ACCC (Group 1, n = 56 patients); progressive disease while receiving ACCC after an intervening response to the drug (Group 2, n = 84); progressive disease within 6 months of last dose of ACCC (Group 3, n = 233); and progressive disease within 12 months of last dose of ACCC (Group 4, n = 272). Second- and third-line therapies administered to these patients included methotrexate, doxorubicin, mitoxantrone, bisantrene, vinblastine, vindesine, melphalan, mitomycin, cisplatin, etoposide and others, but not taxanes. The distribution of patients' characteristics was similar between the four groups, as was the use of second- and third-line regimens. Response rate (RR) to second-line chemotherapy were 5% and 7.7% for Group 1 and Group 2 respectively. In contrast, RR to second-line chemotherapy were 21.6% and 15% for Group 3 and 4. The differences in response rate between the combination of Groups 1 and 2 and Groups 3 or 4 were significant (P = 0.005 and P = 0.04 respectively). These results indicate that strictly defined anthracycline resistance as defined in Groups 1 and 2 is associated with resistance to many other cytotoxic drugs. The definitions used in Groups 3 and 4 include many patients with responsive tumours, and a more favourable prognosis. © 2000 Cancer Research Campaign

Keywords: anthracycline resistance, breast cancer, clinical definition

Full Text

The Full Text of this article is available as a PDF (57.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Creech R. H., Catalano R. B., Shah M. K., Dayal H. An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer. Cancer. 1983 Mar 15;51(6):1034–1040. doi: 10.1002/1097-0142(19830315)51:6<1034::aid-cncr2820510611>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  2. Degardin M., Bonneterre J., Hecquet B., Pion J. M., Adenis A., Horner D., Demaille A. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol. 1994 May;5(5):423–426. doi: 10.1093/oxfordjournals.annonc.a058873. [DOI] [PubMed] [Google Scholar]
  3. Holmes F. A., Valero V., Walters R. S., Theriault R. L., Booser D. J., Fraschini G., Buzdar A. U., Frye D., Gibbs H. R., Hortobagyi G. N. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993;(15):161–169. [PubMed] [Google Scholar]
  4. Hortobagyi G. N., Buzdar A. U. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin. 1995 Jul-Aug;45(4):199–226. doi: 10.3322/canjclin.45.4.199. [DOI] [PubMed] [Google Scholar]
  5. Hortobagyi G. N. Management of breast cancer: status and future trends. Semin Oncol. 1995 Oct;22(5 Suppl 12):101–107. [PubMed] [Google Scholar]
  6. Hortobagyi G. N., Smith T. L., Legha S. S., Swenerton K. D., Gehan E. A., Yap H. Y., Buzdar A. U., Blumenschein G. R. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec;1(12):776–786. doi: 10.1200/JCO.1983.1.12.776. [DOI] [PubMed] [Google Scholar]
  7. Hortobágyi G. N., Buzdar A. U. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs. 1993;45 (Suppl 2):10–19. doi: 10.2165/00003495-199300452-00004. [DOI] [PubMed] [Google Scholar]
  8. Jones S., Winer E., Vogel C., Laufman L., Hutchins L., O'Rourke M., Lembersky B., Budman D., Bigley J., Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct;13(10):2567–2574. doi: 10.1200/JCO.1995.13.10.2567. [DOI] [PubMed] [Google Scholar]
  9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  10. Pivot X., Asmar L., Hortobagyi G. N. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). Int J Oncol. 1999 Aug;15(2):381–386. [PubMed] [Google Scholar]
  11. Ravdin P. M., Burris H. A., 3rd, Cook G., Eisenberg P., Kane M., Bierman W. A., Mortimer J., Genevois E., Bellet R. E. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995 Dec;13(12):2879–2885. doi: 10.1200/JCO.1995.13.12.2879. [DOI] [PubMed] [Google Scholar]
  12. Seidman A. D., Norton L., Reichman B. S., Crown J. P., Yao T. J., Heelan R., Hakes T. B., Lebwohl D. E., Gilewski T. A., Surbone A. Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol. 1993 Aug;20(4 Suppl 3):40–45. [PubMed] [Google Scholar]
  13. Valero V., Holmes F. A., Walters R. S., Theriault R. L., Esparza L., Fraschini G., Fonseca G. A., Bellet R. E., Buzdar A. U., Hortobagyi G. N. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec;13(12):2886–2894. doi: 10.1200/JCO.1995.13.12.2886. [DOI] [PubMed] [Google Scholar]
  14. Vermorken J. B., ten Bokkel Huinink W. W., Mandjes I. A., Postma T. J., Huizing M. T., Heimans J. J., Beijnen J. H., Bierhorst F., Winograd B., Pinedo H. M. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol. 1995 Aug;22(4 Suppl 8):16–22. [PubMed] [Google Scholar]
  15. Walters R. S., Frye D., Buzdar A. U., Holmes F. A., Hortobagyi G. N. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15;69(2):476–481. doi: 10.1002/1097-0142(19920115)69:2<476::aid-cncr2820690234>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  16. Wilson W. H., Berg S. L., Bryant G., Wittes R. E., Bates S., Fojo A., Steinberg S. M., Goldspiel B. R., Herdt J., O'Shaughnessy J. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol. 1994 Aug;12(8):1621–1629. doi: 10.1200/JCO.1994.12.8.1621. [DOI] [PubMed] [Google Scholar]
  17. Yau J. C., Yap Y. Y., Buzdar A. U., Hortobagyi G. N., Bodey G. P., Blumenschein G. R. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer. 1985 Jan 15;55(2):337–340. doi: 10.1002/1097-0142(19850115)55:2<337::aid-cncr2820550205>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES